

## Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review

URL:	<a href="https://marketpublishers.com/r/A11463219BCEN.html">https://marketpublishers.com/r/A11463219BCEN.html</a>
Date:	April 19, 2016
Pages:	56
Price:	US\$ 125.00
ID:	A11463219BCEN

Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

### Highlights

Ariad Pharmaceuticals Inc (Ariad) focuses on the discovery, development and marketing of small-molecule oncology therapies. Its products are indicated to treat chronic and acute leukemia, lung cancer and other difficult to treat cancers. The company's lead product, Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukemia (CML). Ariad's pipeline portfolio comprises three promising molecules including Iclusig, a novel oral multi-targeted kinase inhibitor; Brigatinib, an anaplastic lymphoma kinase inhibitor; and AP32788, a drug candidate, for the treatment of patients with NSCLC with specific mutations in the EGFR or HER2 kinases. Additionally, the company's research and development efforts are focused on exploring cell-signaling pathways and discovering new molecules that interfere with the aberrant signaling pathways of cells and aid in treatment of cancers. Ariad is headquartered in Massachusetts, the US.

### Ariad Pharmaceuticals, Inc. Key Recent Developments

Mar 29, 2016: ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review

Mar 22, 2016: ARIAD Reports Inducement Grant to New Chief Financial Officer

Mar 11, 2016: ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer

Feb 23, 2016: ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress

Jan 15, 2016: ARIAD Reports Inducement Grant to New Chief Executive Officer

### **Key benefits of buying this profile include:**

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## **Table of Content**

### **SECTION 1 - ABOUT THE COMPANY**

Ariad Pharmaceuticals, Inc. - Key Facts

Ariad Pharmaceuticals, Inc. - Key Employees

Ariad Pharmaceuticals, Inc. - Key Employee Biographies

Ariad Pharmaceuticals, Inc. - Major Products and Services

Ariad Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data

Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area

Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase

Ariad Pharmaceuticals, Inc. - History

Ariad Pharmaceuticals, Inc. - Company Statement

Ariad Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Ariad Pharmaceuticals, Inc. - Business Description  
Ariad Pharmaceuticals, Inc. - Corporate Strategy  
Ariad Pharmaceuticals, Inc. - SWOT Analysis  
SWOT Analysis - Overview  
Ariad Pharmaceuticals, Inc. - Strengths  
Strength - Research and Development Activities  
Strength - Lead Candidate: Iclusig  
Ariad Pharmaceuticals, Inc. - Weaknesses  
Weakness - History of Operating Losses  
Ariad Pharmaceuticals, Inc. - Opportunities  
Opportunity - Orphan Drug Designation: Ponatinib  
Opportunity - Market Potential: Iclusig  
Opportunity - Product Pipeline  
Ariad Pharmaceuticals, Inc. - Threats  
Threat - Competitive Pressures  
Threat - Intellectual Property Risk  
Threat - Dependence on Third Parties  
Ariad Pharmaceuticals, Inc. - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016  
Ariad Pharmaceuticals, Inc., Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Mar 29, 2016: ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review  
Mar 22, 2016: ARIAD Reports Inducement Grant to New Chief Financial Officer  
Mar 11, 2016: ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer  
Feb 23, 2016: ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress  
Jan 15, 2016: ARIAD Reports Inducement Grant to New Chief Executive Officer  
Jan 10, 2016: ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors  
Dec 18, 2015: ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer  
Nov 03, 2015: ARIAD Reports Third Quarter 2015 Financial Results and Progress on Strategic Objectives  
Aug 05, 2015: ARIAD Reports Second Quarter 2015 Financial Results and Progress on Strategic Objectives  
May 07, 2015: ARIAD Reports First Quarter 2015 Financial Results and Progress on Strategic Objectives

### **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions

About GlobalData  
Contact Us  
Disclaimer

## LIST OF TABLES

Ariad Pharmaceuticals, Inc., Key Facts  
Ariad Pharmaceuticals, Inc., Key Employees  
Ariad Pharmaceuticals, Inc., Key Employee Biographies  
Ariad Pharmaceuticals, Inc., Major Products and Services  
Ariad Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area  
Ariad Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage  
Ariad Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase  
Ariad Pharmaceuticals, Inc., History  
Ariad Pharmaceuticals, Inc., Subsidiaries  
Ariad Pharmaceuticals, Inc., Key Competitors  
Ariad Pharmaceuticals, Inc., Ratios based on current share price  
Ariad Pharmaceuticals, Inc., Annual Ratios  
Ariad Pharmaceuticals, Inc., Interim Ratios  
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016  
Ariad Pharmaceuticals, Inc., Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## LIST OF FIGURES

Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area  
Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase  
Ariad Pharmaceuticals, Inc., Performance Chart (2011 - 2015)  
Ariad Pharmaceuticals, Inc., Ratio Charts  
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

### I would like to order:

**Product name:** Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review  
**Product link:** <https://marketpublishers.com/r/A11463219BCEN.html>  
**Product ID:** A11463219BCEN  
**Price:** US\$ 125.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/A11463219BCEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**